Nguyen M, Walimbe T, Woolley A, Paderi J, Panitch A
Proteoglycan Res. 2024; 1(2).
PMID: 38884098
PMC: 11178347.
DOI: 10.1002/pgr2.3.
Janjic M, Pappa F, Karagkiozaki V, Gitas C, Ktenidis K, Logothetidis S
Int J Nanomedicine. 2017; 12:6343-6355.
PMID: 28919738
PMC: 5587164.
DOI: 10.2147/IJN.S138261.
Lee J, Yoo J, Atala A, Lee S
Biomaterials. 2012; 33(28):6709-20.
PMID: 22770570
PMC: 3760265.
DOI: 10.1016/j.biomaterials.2012.06.017.
Garg H, Mrabat H, Yu L, Freeman C, Li B, Zhang F
Carbohydr Res. 2010; 345(9):1084-7.
PMID: 20399420
PMC: 2891731.
DOI: 10.1016/j.carres.2010.03.026.
Mrabat H, Garg H, Hales C
J Cell Physiol. 2009; 221(3):603-8.
PMID: 19653229
PMC: 2755647.
DOI: 10.1002/jcp.21891.
Significance of the 2-O-sulfo group of L-iduronic acid residues in heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells.
Garg H, Mrabat H, Yu L, Freeman C, Li B, Zhang F
Carbohydr Res. 2008; 343(14):2406-10.
PMID: 18656855
PMC: 4745410.
DOI: 10.1016/j.carres.2008.06.022.
Heparin and structurally related polymers attenuate eotaxin-1 (CCL11) release from human airway smooth muscle.
Kanabar V, Page C, Simcock D, Karner C, Mahn K, OConnor B
Br J Pharmacol. 2008; 154(4):833-42.
PMID: 18536736
PMC: 2439852.
DOI: 10.1038/bjp.2008.109.
Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecular-weight heparin derivative.
Garg H, Hales C, Yu L, Butler M, Islam T, Xie J
Carbohydr Res. 2006; 341(15):2607-12.
PMID: 16920092
PMC: 4129652.
DOI: 10.1016/j.carres.2006.07.014.
Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle.
Kanabar V, Hirst S, OConnor B, Page C
Br J Pharmacol. 2005; 146(3):370-7.
PMID: 16025136
PMC: 1576283.
DOI: 10.1038/sj.bjp.0706333.
Identification of the heparin-binding domains of the interferon-induced protein kinase, PKR.
Fasciano S, Hutchins B, Handy I, Patel R
FEBS J. 2005; 272(6):1425-39.
PMID: 15752359
PMC: 3969814.
DOI: 10.1111/j.1742-4658.2005.04575.x.
Engineering of bypass conduits to improve patency.
Rashid S, Salacinski H, Fuller B, Hamilton G, Seifalian A
Cell Prolif. 2004; 37(5):351-66.
PMID: 15377334
PMC: 6495671.
DOI: 10.1111/j.1365-2184.2004.00318.x.
Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells.
Mason H, Nowak R, Morton C, Castellot Jr J
Am J Pathol. 2003; 162(6):1895-904.
PMID: 12759246
PMC: 1868134.
DOI: 10.1016/S0002-9440(10)64323-4.
Expression of heparan sulphate N-deacetylase/N-sulphotransferase by vascular smooth muscle cells.
Bingley J, Hayward I, Girjes A, Campbell G, Humphries D, Stow J
Histochem J. 2002; 34(3-4):131-7.
PMID: 12495219
DOI: 10.1023/a:1020938430120.
Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo.
Lovich M, Edelman E
Proc Natl Acad Sci U S A. 1999; 96(20):11111-6.
PMID: 10500138
PMC: 17995.
DOI: 10.1073/pnas.96.20.11111.
Characterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis.
Patel M, Refson J, Schachter M, Hughes A
Br J Pharmacol. 1999; 127(2):361-8.
PMID: 10385234
PMC: 1566031.
DOI: 10.1038/sj.bjp.0702559.
Brachytherapy with iridium-192 HDR to prevent from restenosis in peripheral arteries. An update.
Liermann D, Kirchner J, Bauernsachs R, Schopohl B, Bottcher H
Herz. 1998; 23(6):394-400.
PMID: 9816526
DOI: 10.1007/BF03043605.
Proliferative effect of ammodytin L from the venom of Vipera ammodytes on 208F rat fibroblasts in culture.
Rufini S, Cesaroni M, Balestro N, Luly P
Biochem J. 1996; 320 ( Pt 2):467-72.
PMID: 8973554
PMC: 1217953.
DOI: 10.1042/bj3200467.
The effect of pancreatopeptidase E (elastase) on anastomotic intimal thickness in two types of vascular prosthesis.
Akimoto F
Surg Today. 1995; 25(12):1027-33.
PMID: 8645935
DOI: 10.1007/BF00311687.
Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells.
Kenagy R, Nikkari S, Welgus H, Clowes A
J Clin Invest. 1994; 93(5):1987-93.
PMID: 8182130
PMC: 294307.
DOI: 10.1172/JCI117191.
Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity.
Schmitt-Graff A, Desmouliere A, Gabbiani G
Virchows Arch. 1994; 425(1):3-24.
PMID: 7921410
DOI: 10.1007/BF00193944.